LONDON, Dec 16 (Reuters) – The U.S. Food and Drug Administration has approved GSK’s add-on drug to treat asthma and a chronic inflammatory sinus condition, the drugmaker said on Tuesday, paving the way for a less frequently dosed treatment option for patients to enter the market.
(Reporting by Bhanvi Satija in London, Sahil Pandey and Sneha S K in Bengaluru; Editing by Tasim Zahid and Shailesh Kuber)
Keyword: Text NEWS to 39327*
Details: Breaking News Alerts
Messages: expect up to 1 per week
Keyword: Text WEATHER to 39327*
Details: Daily Weather Forecast
Messages: expect up to 7 per week
Sponsor: King’s Campers
Keyword: Text TRAFFIC to 39327*
Details: Traffic and road alerts
Messages: expect up to 5 per week
*Message & data rates may apply. Text STOP to 39327 to quit. Text HELP for help or visit www.vibes.com/help/ for support. No purchase necessary. Marketing text messages generated by an automated dialer will be delivered to the phone number you provide at opt-in
Comments